Surgical Site Infection Clinical Trial
Official title:
A Prospective Dose-Escalation Trial of the Pharmacokinetics and Preliminary Safety of Intrasite Lyophilized Vancomycin to Prevent Wound Infections in Instrumented Spinal Surgery
Surgical wound infections remain a serious problem despite aseptic techniques and the use of
prophylactic systemic antibiotics. Such infections can occur at rates up to ~20% in high-risk
patients receiving long segment instrumented spinal fusions for deformity correction and
present potentially catastrophic consequences. Given this, the high cost of treatment, and a
payer system unable to support such expenses, investigators must make every effort to find
new cost-effective ways to prevent these complications.
Increasingly surgeons have sought to address this problem by placing lyophilized Vancomycin
into spinal surgery wounds immediately prior to wound closure. This method, known as
"intrasite" application, is adapted from techniques used to prevent infection in joint
replacement surgeries. The motivation for this practice is to maximize antibiotic
concentration within the wound while minimizing systemic concentration and toxicity, (the
inverse of the situation when using IV antibiotics). While the popularity of intrasite
delivery has grown rapidly, this has occurred without prospective scientific evidence.
Recently, three retrospective papers including nearly 2,500 treated patients, indicated that
intrasite Vancomycin reduces wound infections without increasing adverse events[1-3].
However, there are no published data on the dosing or pharmacokinetics of intrasite
Vancomycin, let alone prospective trials of its efficacy and safety.
The investigators propose to perform the first prospective trial of intrasite Vancomycin
pharmacokinetics and safety. Study objectives will include standardizing application and
dosing, defining peak/trough concentrations and clearance parameters, verifying bactericidal
potency, and dose selection for use in future studies. This will be accomplished by enrolling
groups of patients (n=10) to receive one of three doses of intrasite lyophilized Vancomycin
(3, 6 or 12 mg/cm2), prior to wound closure. Vancomycin concentrations in venous blood and
wound seroma fluid will be measured at regular intervals after surgery to establish
pharmacokinetic parameters. Preliminary data regarding local and systemic adverse events
including wound healing, fusion rate, and toxicity will be prospectively collected. The
ultimate goal of this learning-phase study is to gather sufficient information regarding
application, dosing, pharmacokinetics, measurement strategies, and adverse events to prepare
for a Phase III efficacy trial.
Despite extremely close attention to aseptic technique and the use of prophylactic IV
antibiotics, wound infection rates for posterior instrumented spinal surgery have been as
high as ~20% in published studies[4-13]. Such infections can be devastating for patients,
frequently requiring multiple re-operations to remove and then replace spinal implants,
lengthy hospital stays, prolonged courses of intravenous antibiotics, pain, immobility, and
increased risk of other complications. While the cost of the initial surgical episode can be
upwards of $250,000, the total cost of care can increase to more than quadruple this number
when complications like wound infection occur[14, 15]. Given the impetus to decrease
healthcare costs and a federal reimbursement policy denying payment for any care surrounding
a wound infection, it is critical to search for cost-effective ways of preventing surgical
wound infections[14, 16].
For several decades the standard of care in North America for surgical wound infection
prophylaxis has been IV cephalosporin administration within one hour of incision, followed by
interval IV dosing for 24 to 48hrs post-procedure[5, 13]. In some settings these antibiotics
now effectively treat less than half of identified infection-causing organisms[17, 18]. In
response, some groups of surgeons, including at the investigators' own institution, have
begun placing lyophilized Vancomycin into the surgical wound bed at the conclusion of the
procedure in an effort to further reduce wound infection rates[1-3]. The rationale behind
this intrasite antibiotic application is to increase local concentrations of antibiotic to
many times the minimally inhibitory concentration (MIC) for even moderately-resistant
gram-positive organisms, thereby increasing the bacterial kill rate[3]. It is also thought
that local antibiotic application should minimize blood concentrations of the drug, thereby
minimizing systemic complications like renal toxicity. Additionally, it is hypothesized that
intrasite antibiotic therapy could be less inclined to generate resistant organisms due to a
steep concentration gradient from the wound to the systemic circulation. The site of
potential infection (the wound) receives a dose of antibiotic vastly exceeding the saturation
concentration for bactericidal effect while the systemic concentration remains extremely low.
Bacteria should therefore be completely exterminated in the area of the wound or elsewhere
exposed to such a minimal concentration of Vancomycin that selection for resistant organisms
is avoided.
While none of these hypotheses have been rigorously or prospectively tested, three
retrospective studies have recently published a total of 2,479 spinal fusion patients treated
with intrasite Vancomycin for wound infection prophylaxis[1-3]. The largest of these studies
demonstrated a 0.99% infection rate in the treatment group, among the lowest rates ever
published[1]. Two of the studies showed large and statistically significant decreases in the
wound infection rate, compared to historical controls, when using intrasite Vancomycin in
addition to standard of care IV cephalosporins. Preliminary evidence in one study also
indicated high levels of Vancomycin within the wound and low or undetectable levels within
the blood following surgery[3]. All of these studies specifically cited that no adverse
events had been observed related to the treatment[1-3].
If intrasite Vancomycin proves to be safe and effective for preventing spinal fusion surgical
site infections, the treatment will offer great clinical value both for reducing morbidity
and also for decreasing large unsupported costs. A future large prospective efficacy trial
would be required to provide high-level evidence for this new mode of antibiotic therapy in
order to justify wide-spread adoption of the practice in spine surgery. Such data in any
population might also be generalizable to surgical wounds at large and prompt a paradigm
shift in infection prophylaxis for all types of surgical wounds. The proposed study addresses
necessary prerequisites for such a large-scale efficacy trial, including basic
pharmacokinetic and preliminary prospective safety data.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04096885 -
The Inselspital Surgical Cohort Study
|
||
Terminated |
NCT03820648 -
Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT04067843 -
Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
|
N/A | |
Terminated |
NCT04042077 -
Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
|
Phase 3 | |
Completed |
NCT05841576 -
Anaesthetic Management Guided by COMET Measurements
|
N/A | |
Withdrawn |
NCT05338281 -
NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT01697748 -
Prospective Study on Cesarean Wound Outcomes
|
N/A | |
Terminated |
NCT01789697 -
Text Message Study
|
N/A | |
Recruiting |
NCT05966961 -
Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
|
||
Recruiting |
NCT05077592 -
Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections
|
Phase 4 | |
Recruiting |
NCT05763602 -
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
|
Phase 4 | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Recruiting |
NCT03221023 -
Intrawound Vancomycin Prophylaxis for Neural Stimulator
|
Phase 2/Phase 3 | |
Completed |
NCT03257202 -
Topical Treatment and Prevalence of P. Acnes
|
Phase 2 | |
Completed |
NCT06154720 -
Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
|
||
Not yet recruiting |
NCT06465901 -
A Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI
|
N/A | |
Not yet recruiting |
NCT04820075 -
Efficacy of an Intervention to Improve the Preoperative Shower in Scheduled Surgery
|
N/A | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT04496180 -
Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy
|
N/A |